TY - JOUR
T1 - Cardiac transplantation for radiation-induced cardiomyopathy
T2 - The Mayo Clinic experience
AU - Saxena, Pankaj
AU - Joyce, Lyle D.
AU - Daly, Richard C.
AU - Kushwaha, Sudhir S.
AU - Schirger, John A.
AU - Rosedahl, Jordan
AU - Dearani, Joseph A.
AU - Kara, Tomas
AU - Edwards, Brooks S.
N1 - Funding Information:
We appreciate the help of Walter Kremers, PhD, Chen Fan, and Sandra Schwantz in data organization and collection. B.S.E., J.A.S., and T.K. were supported by the European Regional Development Fund—Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123 ).
Publisher Copyright:
© 2014 The Society of Thoracic Surgeons.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background High-dose radiotherapy to the mediastinum for the treatment of malignancies causes injury to the intrathoracic organs. Coronary artery disease, valvular dysfunction, cardiomyopathy, and chronic constrictive pericarditis are common cardiovascular sequelae during long-term follow-up. Cardiac transplantation is indicated for the surgical treatment of heart failure due to radiation-induced end-stage cardiac disease.Methods A retrospective study of radiation-induced cardiomyopathy requiring cardiac transplantation was undertaken from December 1992 to August 2010.Results Twelve patients (7 men, 5 women), with a mean age of 47.4 years, underwent orthotopic cardiac transplantation. Redo cardiac operations were performed in 9 patients. Lymphoma was the primary malignancy in all patients. Adjuvant chemotherapy was used in 9 patients, and splenectomy was performed in 7. Restrictive cardiomyopathy (n = 8) was the predominant diagnosis. Restrictive lung disease was present in 10 patients (83%). Postoperative chronic kidney injury developed in 3 patients (25%). Hospital mortality was 8.3%. Survival at 1, 5, and 10 years was 91.7%, 75%, and 46.7%, respectively. The overall mean follow-up was 7.7 years (median, 6.1; range, 1.8 to 16.4 years). Late respiratory failure accounted for 3 deaths.Conclusions Cardiac transplantation provides satisfactory medium-term to long-term outcome in patients with radiation-induced cardiomyopathy. Secondary malignancies, kidney injury, and respiratory failure contribute to significant postoperative morbidity and death.
AB - Background High-dose radiotherapy to the mediastinum for the treatment of malignancies causes injury to the intrathoracic organs. Coronary artery disease, valvular dysfunction, cardiomyopathy, and chronic constrictive pericarditis are common cardiovascular sequelae during long-term follow-up. Cardiac transplantation is indicated for the surgical treatment of heart failure due to radiation-induced end-stage cardiac disease.Methods A retrospective study of radiation-induced cardiomyopathy requiring cardiac transplantation was undertaken from December 1992 to August 2010.Results Twelve patients (7 men, 5 women), with a mean age of 47.4 years, underwent orthotopic cardiac transplantation. Redo cardiac operations were performed in 9 patients. Lymphoma was the primary malignancy in all patients. Adjuvant chemotherapy was used in 9 patients, and splenectomy was performed in 7. Restrictive cardiomyopathy (n = 8) was the predominant diagnosis. Restrictive lung disease was present in 10 patients (83%). Postoperative chronic kidney injury developed in 3 patients (25%). Hospital mortality was 8.3%. Survival at 1, 5, and 10 years was 91.7%, 75%, and 46.7%, respectively. The overall mean follow-up was 7.7 years (median, 6.1; range, 1.8 to 16.4 years). Late respiratory failure accounted for 3 deaths.Conclusions Cardiac transplantation provides satisfactory medium-term to long-term outcome in patients with radiation-induced cardiomyopathy. Secondary malignancies, kidney injury, and respiratory failure contribute to significant postoperative morbidity and death.
UR - http://www.scopus.com/inward/record.url?scp=84919459134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919459134&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2014.06.056
DO - 10.1016/j.athoracsur.2014.06.056
M3 - Article
C2 - 25443015
AN - SCOPUS:84919459134
SN - 0003-4975
VL - 98
SP - 2115
EP - 2121
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 6
ER -